Bio-Rad Labs (BIO) Misses Q3 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Bio-Rad Reports Third-Quarter 2018 Financial Results
November 1, 2018 4:30 PM EDTHERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2018.
Third-quarter 2018 net sales were $545.1 million, an increase of 2.1 percent compared to $534.1 million reported for the third quarter of 2017. On a currency-neutral basis, quarterly sales increased 3.4 percent compared to the same period in 2017, reflecting growth across the business. Third-quarter gross margin was 52.6 percent compared to 56.0 percent during the third quarter in 2017. Gross margin in the third quarter of 2018 was impacted by higher costs for service, warranty... More
